More recently, promising antitumor activity was seen with programmed cell death protein 1 (PD-1) inhibitors among patients with NKTCL who failed asparaginase-based combination therapy. This evidence concerns the gene PDCD1 and extranodal nasal NK/T cell lymphoma.